CLDX
Celldex Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.24
−1.90%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$1.02
- Revenue estimate
- $722.6K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.94
- EPS estimate
- -$1.06
- Revenue actual
- $22.0K
- Revenue estimate
- $734.9K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -3.1%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $66
- PT range
- $50 – $100
- Analysts
- 6
6 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$1.06 | -$0.94 | Beat 11.32% | $22.0K |
| May 7, 2026 | -$1.15 | -$1.18 | Miss -2.86% | — |
| Feb 25, 2026 | -$1.00 | -$1.22 | Miss -22.00% | $75.0K |
| Aug 7, 2025 | -$0.86 | -$0.85 | Beat 1.16% | $730.0K |
| May 8, 2025 | -$0.75 | -$0.81 | Miss -8.00% | $695.0K |
| Feb 27, 2025 | -$0.73 | -$0.71 | Beat 2.74% | $1.2M |
| Feb 26, 2024 | -$0.76 | -$0.57 | Beat 25.00% | $4.1M |
| Nov 2, 2023 | -$0.67 | -$0.81 | Miss -20.90% | $1.5M |
| May 4, 2023 | -$0.63 | -$0.62 | Beat 1.59% | $967.0K |
| Feb 28, 2023 | -$0.59 | -$0.56 | Beat 5.08% | $1.6M |
| Nov 9, 2022 | -$0.57 | -$0.57 | In line | $407.0K |
| May 5, 2022 | -$0.46 | -$0.49 | Miss -6.52% | $174.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026